United Health Products (UEEC) Q2 2024 earnings summary

Executive summary

• Focused on obtaining FDA Class III PMA for HemoStyp hemostatic gauze, pausing commercial activities to prioritize regulatory approval.

• No revenue generated in Q2 or first half of 2024 due to resource allocation toward regulatory efforts.

• Net loss for Q2 2024 was $432,021, an improvement from $522,911 in Q2 2023; six-month net loss was $883,959, down from $1,665,617 year-over-year.

• Operating expenses decreased significantly due to lower litigation, legal, and R&D costs.

Financial highlights

• Cash and cash equivalents at June 30, 2024: $18,754, down from $95,420 at year-end 2023.

• Negative working capital of $2,064,538 as of June 30, 2024.

• Net cash used in operating activities for six months ended June 30, 2024: $693,481, improved from $1,019,370 in the prior year period.

• Net cash provided by financing activities: $616,815 for the first half of 2024, primarily from equity sales.

• No revenue recognized in Q2 or first half 2024.

Outlook and guidance

• Awaiting FDA response to PMA application; review paused pending response to deficiency letter with 40 comments.

• No assurance of FDA approval; business strategy may require significant change if not granted.

• Exploring potential sale, merger, or commercial partnerships contingent on regulatory outcome.